EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Factors influencing the early neurological deterioration in intracranial branch atheromatous diseases

Ichiro Deguchi, Shinako Fujiwara, Noriko Arai, Toru Nakagami, Ryutaro Kimura, Kiichiro Oryu, Kaito Watanabe, Yuji Kato, Takeshi Hayashi, Shinichi Takahashi, Satoshi Suda

Neurology and Clinical Neuroscience · 2024-07 · 12 (4) · 217-224

DOI: 10.1111/ncn3.12800 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Intracranial branch atheromatous disease (BAD)‐type cerebral infarction is often associated with a progressive worsening of neurological symptoms in the acute phase. Aim To investigate the factors influencing the occurrence of early neurological deterioration (END) in patients with BAD. Methods We included and evaluated 198 consecutive patients (150 patients with lenticulostriate artery [LSA‐BAD] and 48 patients with paramedian pontine artery [PPA‐BAD]) with onset within 24 h and with a modified Rankin scale score of ≤1 before admission for END retrospectively out of 235 patients with BAD‐type cerebral infarction admitted to our hospital from January 2019 to March 2023. Results END was observed in 26 (17%) and 15 (31%) patients with LSA‐BAD and PPA‐BAD, respectively. Patients in the END group with LSA‐BAD had significantly higher rates of diabetes mellitus and blood glucose (BG) levels on admission and lower rates of initial clopidogrel loading therapy than those in the non‐END group. Patients in the END group with PPA‐BAD had significantly higher BG levels on admission than those in the non‐END group. In LSA‐BAD multivariate analysis, the BG level on admission and initial clopidogrel loading were identified as factors influencing END (BG level [per 10 mg/dL], odds ratio [OR] 1.084, 95% confidence interval [CI] 1.008–1.166; initial clopidogrel loading, OR 0.302, 95% CI 0.101–0.901). Conclusions Higher BG levels at stroke onset were associated with END in patients with LSA‐BAD and PPA‐BAD. Additionally, initial clopidogrel loading therapy suppressed END in patients with LSA‐BAD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →